君實生物(688180.SH):與邁威生物就阿達木單抗注射液合作開發協議簽訂補充協議
格隆匯3月27日丨君實生物(688180.SH)公佈,公司、公司全資子公司蘇州衆合生物醫藥科技有限公司(簡稱“蘇州衆合”)、邁威(上海)生物科技股份有限公司(簡稱“邁威生物”)、邁威生物全資子公司江蘇泰康生物醫藥有限公司(簡稱“泰康生物”,上述主體合稱爲“合同各方”)簽訂《關於<重組人源抗TNF-α單克隆抗體注射液合作開發協議>之補充協議》,對公司作爲藥品上市許可持有人(MarketingAuthorizationHolder,簡稱“MAH”)期間的權益分享條款進行重新約定:1、針對重組人源抗TNF-α單克隆抗體注射液(現稱“阿達木單抗注射液”,商品名:君邁康)的中國大陸區域內銷售權益,公司負責君邁康的生產,按銷售發貨淨收入的40%享有國內銷售權益;邁威生物負責君邁康的推廣,按銷售發貨淨收入的60%享有國內銷售權益。2、公司與邁威生物按50%:50%的比例分擔君邁康的國內研發費用。3、公司與邁威生物按50%:50%的比例分享君邁康的國際銷售權益。本補充協議自合同各方簽字蓋章後於2025年1月1日生效。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.